论文部分内容阅读
目的:探讨非小细胞肺癌患者(NSCLC)血清血管内皮生长因子C(VEGF-C)表达水平及其与临床病理特征之间的关系。方法:采集20例健康体检者、30例肺炎患者及60例NSCLC患者血清,用ELISA方法检测VEGF-C表达水平。结果:NSCLC患者血清VEGF-C水平远高于正常健康人群组(P<0.01)和肺炎患者(P<0.05);有淋巴结转移的NSCLC患者血清VEGF-C水平明显高于无淋巴结转移者(P<0.05);Ⅲ、Ⅳ期NSCLC患者血清VEGF-C水平明显远高于Ⅰ、Ⅱ期患者(P<0.01);NSCLC患者血清VEGF-C水平与患者生存时间呈负相关(P<0.05)。结论:NSCLC患者血清VEGF-C的表达与病情进展密切相关,并可作为一种有用的预后指标。
Objective: To investigate the relationship between the expression of vascular endothelial growth factor C (VEGF-C) and the clinicopathological features in patients with non-small cell lung cancer (NSCLC). Methods: Serum samples from 20 healthy subjects, 30 pneumonia patients and 60 NSCLC patients were collected. The expression of VEGF-C was detected by ELISA. Results: Serum levels of VEGF-C in patients with NSCLC were significantly higher than those in healthy controls (P <0.01) and patients with pneumonia (P <0.05). Serum levels of VEGF-C in NSCLC patients with lymph node metastasis were significantly higher than those without lymph node metastasis (P <0.05). The serum levels of VEGF-C in stage Ⅲ and Ⅳ NSCLC patients were significantly higher than those in stage Ⅰ and Ⅱ patients (P <0.01). The serum levels of VEGF-C in NSCLC patients were negatively correlated with the patients’ . Conclusion: The expression of VEGF-C in serum of patients with NSCLC is closely related to the progression of the disease, and can be used as a useful prognostic indicator.